Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
94 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Colitis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H2 2017, provides an overview of the Colitis (Gastrointestinal) pipeline landscape. Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 2, 19 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively. Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Colitis - Overview Colitis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Colitis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Colitis - Companies Involved in Therapeutics Development Akebia Therapeutics Inc Alpha Cancer Technologies Inc Apollo Endosurgery Inc Bristol-Myers Squibb Company Concenter BioPharma Silkim Ltd Cosmo Pharmaceuticals NV Dr. Falk Pharma GmbH EA Pharma Co Ltd Genfit SA Immuron Ltd Ogeda SA Pfizer Inc RDD Pharma Ltd Saniona AB Sigmoid Pharma Ltd Synovo GmbH Thetis Pharmaceuticals LLC Colitis - Drug Profiles ACT-101 - Drug Profile Product Description Mechanism Of Action R&D Progress AcTMP-1 - Drug Profile Product Description Mechanism Of Action R&D Progress AKB-6899 - Drug Profile Product Description Mechanism Of Action R&D Progress AN-346 - Drug Profile Product Description Mechanism Of Action R&D Progress Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Antibody for Colitis - Drug Profile Product Description Mechanism Of Action R&D Progress Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile Product Description Mechanism Of Action R&D Progress APY-0201 - Drug Profile Product Description Mechanism Of Action R&D Progress BC-1215 - Drug Profile Product Description Mechanism Of Action R&D Progress BMS-986104 - Drug Profile Product Description Mechanism Of Action R&D Progress budesonide - Drug Profile Product Description Mechanism Of Action R&D Progress CSA-13 - Drug Profile Product Description Mechanism Of Action R&D Progress CSY-0073 - Drug Profile Product Description Mechanism Of Action R&D Progress dimethyloxalylglycine - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile Product Description Mechanism Of Action R&D Progress elafibranor - Drug Profile Product Description Mechanism Of Action R&D Progress ESN-601 - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate PD-L1 for Colitis and Graft Versus Host Disease - Drug Profile Product Description Mechanism Of Action R&D Progress GFC-101 - Drug Profile Product Description Mechanism Of Action R&D Progress IMM-124E - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Inhibit LTC4 for Colitis - Drug Profile Product Description Mechanism Of Action R&D Progress NK-007 - Drug Profile Product Description Mechanism Of Action R&D Progress Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile Product Description Mechanism Of Action R&D Progress PF-06425090 - Drug Profile Product Description Mechanism Of Action R&D Progress RDD-2007 - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile Product Description Mechanism Of Action R&D Progress rifamycin CR - Drug Profile Product Description Mechanism Of Action R&D Progress RP-182 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Colitis and Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Crohn's Disease and Colitis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides to Inhibit Panx1 for Colitis and Inflammatory Bowel Disease - Drug Profile Product Description Mechanism Of Action R&D Progress TP-317 - Drug Profile Product Description Mechanism Of Action R&D Progress TPC-1022 - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target IL12 and IL23 for Colitis - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target IL23 for Colitis - Drug Profile Product Description Mechanism Of Action R&D Progress VE-303 - Drug Profile Product Description Mechanism Of Action R&D Progress Colitis - Dormant Projects Colitis - Discontinued Products Colitis - Product Development Milestones Featured News & Press Releases Apr 18, 2017: Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Colitis, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Colitis - Pipeline by Akebia Therapeutics Inc, H2 2017 Colitis - Pipeline by Alpha Cancer Technologies Inc, H2 2017 Colitis - Pipeline by Apollo Endosurgery Inc, H2 2017 Colitis - Pipeline by Bristol-Myers Squibb Company, H2 2017 Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H2 2017 Colitis - Pipeline by Cosmo Pharmaceuticals NV, H2 2017 Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2017 Colitis - Pipeline by EA Pharma Co Ltd, H2 2017 Colitis - Pipeline by Genfit SA, H2 2017 Colitis - Pipeline by Immuron Ltd, H2 2017 Colitis - Pipeline by Ogeda SA, H2 2017 Colitis - Pipeline by Pfizer Inc, H2 2017 Colitis - Pipeline by RDD Pharma Ltd, H2 2017 Colitis - Pipeline by Saniona AB, H2 2017 Colitis - Pipeline by Sigmoid Pharma Ltd, H2 2017 Colitis - Pipeline by Synovo GmbH, H2 2017 Colitis - Pipeline by Thetis Pharmaceuticals LLC, H2 2017 Colitis - Dormant Projects, H2 2017 Colitis - Dormant Projects, H2 2017 (Contd..1), H2 2017 Colitis - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
